Ace Therapeutics has announced the introduction of its comprehensive platform of preclinical genetic kidney disease models, aimed at accurately replicating human hereditary renal pathology. This initiative is designed to bolster translational research efforts for drug developers across the globe.
Genetic kidney diseases, which are often the result of inherited pathogenic mutations, present a significant unmet medical need characterised by progressive renal impairment and limited treatment options. To tackle this pressing issue, Ace Therapeutics has developed and validated a range of genetically engineered animal models that encapsulate the essential molecular, histological, and functional characteristics of inherited renal disorders. This innovation facilitates reliable target validation, mechanistic exploration, and the assessment of therapeutic efficacy.
The preclinical genetic kidney disease models from Ace Therapeutics encompass a diverse array of both rare and common hereditary nephropathies. This includes conditions such as Alport Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Fabry Disease, Polycystic Kidney Disease (PKD), and C3 Glomerulopathy. These models employ well-characterised knockout and conditional knockout rodent strains, ensuring that they are both consistent and clinically relevant.
Rigorous quality assurance measures are implemented for each model, including immunofluorescence staining, transmission electron microscopy, molecular expression analysis, and long-term renal function monitoring. These steps are crucial in maintaining the reliability and applicability of the models in a clinical context.
In addition to standard models, Ace Therapeutics provides custom model generation using CRISPR/Cas9 technology. This allows for the creation of tissue-specific or conditional knockout lines targeting novel pathways, thereby further enhancing the versatility of the platform for exploratory and translational research.
All studies conducted by Ace Therapeutics adhere to stringent institutional animal care guidelines. Furthermore, the company offers transparent data packages, comprising both raw and processed results, to facilitate regulatory compliance and publication readiness.
Ace Therapeutics also boasts comprehensive preclinical service capabilities that encompass therapeutic efficacy testing, mechanistic profiling, biomarker development, and advanced imaging analytics. These services enable detailed dose–response evaluations for various therapeutic modalities, including small molecules, antisense oligonucleotides (ASOs), and gene therapies. Noteworthy techniques include single-cell RNA sequencing, urinary exosome analysis, and MRI-based cyst volumetry, which provide in-depth characterisation of the diseases studied.
Among its specialised offerings, Ace Therapeutics conducts gene therapy testing in Fabry disease models. The company employs Gla knockout mice to assess AAV vector tropism, biodistribution, and therapeutic efficacy by measuring globotriaosylceramide (Gb3) accumulation and renal fibrosis, along with other critical disease-related endpoints.
With the launch of these genetic kidney disease models and an expanded suite of preclinical renal research services, Ace Therapeutics strengthens its role as a trusted collaborator for biotechnology and pharmaceutical companies dedicated to advancing innovative therapies for genetic kidney diseases. This commitment supports the discovery and development of transformative treatments for patients worldwide.
Ace Therapeutics is a dedicated provider of preclinical research solutions for nephrology, offering integrated in vivo and in vitro models for chronic kidney disease, polycystic kidney disease, acute kidney injury, diabetic kidney disease, immune-mediated nephropathies, and genetic kidney disorders. The company facilitates comprehensive preclinical drug development, ensuring a focus on translational relevance and scientific integrity.